# Study of INV-202 in Patients With Obesity and Metabolic Syndrome

> **NCT05891834** · PHASE2 · COMPLETED · sponsor: **Inversago Pharma Inc.** · enrollment: 243 (actual)

## Conditions studied

- Obesity
- Metabolic Syndrome

## Interventions

- **DRUG:** INV-202
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05891834
- **Lead sponsor:** Inversago Pharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-08
- **Primary completion:** 2024-06-13
- **Final completion:** 2025-02-14
- **Target enrollment:** 243 (ACTUAL)
- **Last updated:** 2025-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05891834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05891834, "Study of INV-202 in Patients With Obesity and Metabolic Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05891834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*